Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Viatris Inc., junto con sus subsidiarias, opera como una empresa de atención médica en América del Norte, Europa, China, Taiwán, Hong Kong, Japón, Australia, Nueva Zelanda, el resto de Asia, África, América Latina y Medio Oriente. Opera en cuatro segmentos: Mercados Desarrollados, Gran China, JANZ y Mercados Emergentes. La empresa ofrece medicamentos de marca recetados, medicamentos genéricos, medicamentos genéricos complejos y biosimilares.
Traducido automáticamente
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $14.7B | $14.3B | $14.7B | $15.4B | $16.3B | $17.9B | $11.9B | $11.5B | $11.4B | $11.9B | $11.1B | $9.4B | $7.7B | $6.9B | $6.8B | $6.1B | $5.5B | $5.1B | $5.1B | $2.9B | $1.6B |
| Beneficio bruto | $5.1B | $5.0B | $5.6B | $6.4B | $6.5B | $5.6B | $3.8B | $3.9B | $4.0B | $4.8B | $4.7B | $4.2B | $3.5B | $3.0B | $2.9B | $2.6B | $2.2B | $2.1B | $2.1B | $1.2B | $844M |
| % de margen bruto | 34.8% | 35.1% | 38.1% | 41.7% | 40.0% | 31.2% | 31.8% | 33.9% | 35.0% | 40.2% | 42.4% | 44.7% | 45.7% | 44.0% | 42.8% | 41.8% | 40.7% | 40.7% | 40.3% | 40.1% | 52.3% |
| Ingresos operativos (EBIT) | ($87M) | ($2.7B) | $10M | $766M | $1.6B | ($34M) | ($211M) | $716M | $906M | $1.4B | $699M | $1.5B | $1.4B | $1.1B | $1.1B | $1.0B | $722M | $523M | $298M | $372M | $428M |
| % de margen operativo | -0.6% | -18.6% | 0.1% | 5.0% | 9.9% | -0.2% | -1.8% | 6.2% | 7.9% | 12.1% | 6.3% | 15.5% | 17.5% | 16.4% | 16.3% | 16.4% | 13.2% | 10.3% | 5.8% | 12.8% | 26.5% |
| Ingresos netos | ($411M) | ($3.5B) | ($634M) | $55M | $2.1B | ($1.3B) | ($670M) | $17M | $352M | $696M | $480M | $848M | $929M | $624M | $641M | $537M | $345M | $233M | ($196M) | ($1.5B) | $217M |
| % de margen neto | -2.8% | -24.6% | -4.3% | 0.4% | 12.8% | -7.1% | -5.6% | 0.1% | 3.1% | 5.8% | 4.3% | 9.0% | 12.0% | 9.0% | 9.4% | 8.8% | 6.3% | 4.6% | -3.8% | -52.2% | 13.5% |
| EBITDA | $2.6B | ($395M) | $2.8B | $3.5B | $6.4B | $4.5B | $2.0B | $2.7B | $3.0B | $3.2B | $2.1B | $2.3B | $1.9B | $1.6B | $1.7B | $1.5B | $1.1B | $947M | $735M | ($992M) | $683M |
| Beneficio por acción (EPS) | $-0.36 | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 | $-1.11 | $0.03 | $0.68 | $1.30 | $0.92 | $1.70 | $2.34 | $1.58 | $1.52 | $1.22 | $1.05 | $0.76 | $-0.64 | $-5.90 | $0.99 |
| Acciones en circulación (M) | 1,163M | 1,171M | 1,193M | 1,207M | 1,217M | 1,209M | 601M | 516M | 516M | 537M | 520M | 497M | 398M | 394M | 420M | 439M | 329M | 307M | 304M | 257M | 219M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de VTRS. /companies/us/VTRS
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms